Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
NCT04677595
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
Capmatinib
Sponsor
Novartis Pharmaceuticals